We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HIMS Q3 Earnings Call Highlights Marketing Reset and Margin Pressure
Read MoreHide Full Article
Key Takeaways
HIMS Q3 revenues rose 49% to $890.4M, but earnings missed estimates as subscribers fell 100,000 sequentially.
HIMS plans to expand branded weight-loss treatments and ramp up marketing to revive subscriber growth in Q1.
HIMS gross margin fell to 57% from 74%, while international investments prompted cuts to 2026 profit guidance.
Hims & Hers Health, Inc. (HIMS - Free Report) is prioritizing a broader weight-loss offering and international expansion over immediate subscriber gains following its third-quarter 2026 earnings call. Management expects the changes to position the platform for renewed customer acquisition in early 2027.
Revenues rose 49% year over year to $890.4 million, missing the Zacks Consensus Estimate of $893.4 million. The company reported earnings of $0.03 per share, which missed the consensus mark of $0.07. The discussion centered on investment timing, weakening gross margins and the economics of branded treatments.
Hims & Hers Health, Inc. Price, Consensus and EPS Surprise
HIMS Holds Back Marketing Ahead of Weight-Loss Expansion
Chief executive officer Andrew Dudum said that the company deliberately moderated U.S. weight-loss marketing while preparing new medications, pricing options and longer subscription plans. The decision reduced near-term customer acquisition.
Subscribers reached 2.8 million, up 13% year over year but down 100,000 sequentially. Chief financial officer Yemi Okupe linked the decline to restrained domestic spending and international brand transitions.
Asked by Canaccord Genuity about subscriber trends, Okupe said that marketing would intensify around the first-quarter seasonal demand peak. He expects subscriber growth to recover after the expanded offering becomes available.
HIMS Broadens Drug Access Through Two Partners
Dudum highlighted plans to add Eli Lilly's Zepbound and Foundayo alongside Novo Nordisk's Wegovy products, with CagriSema planned once available. Multi-month subscriptions will offer additional pricing flexibility.
A Needham analyst questioned whether the marketing pullback reflected weaker returns. Dudum emphasized product assortment and subscription improvements rather than identifying deteriorating demand as the reason.
Okupe added that the company has previously seen broader selection support acquisition and retention. He expects acquisition benefits beginning in the first quarter, with retention benefits developing through 2027.
HIMS Cuts Profit Outlook Despite International Growth
Okupe narrowed full-year revenue guidance to $3.13 billion-$3.15 billion but lowered adjusted EBITDA guidance to $257 million-$277 million, reflecting planned international pricing and marketing investments and revenue deferrals.
Fourth-quarter guidance calls for revenues of $875 million-$895 million and adjusted EBITDA of $70 million-$90 million. Management also expects at least $20 million of full-year revenue and adjusted EBITDA pressure from membership deferrals.
International revenues reached $233 million, including roughly $135 million from Eucalyptus. Okupe raised his 2026 international revenue expectation to at least $650 million from $600 million as Hims & Hers expands across the United Kingdom, Germany and Australia.
HIMS Faces Branded Drug Margin Trade-Offs
Gross margin fell to 57% from 74% a year earlier, reflecting the growing share of lower-margin branded weight-loss products and international operations.
During Morgan Stanley's questioning, Okupe said the full-quarter contribution from Eucalyptus made international mix particularly significant. He stressed adjusted EBITDA dollars and free cash flow rather than near-term gross margin recovery.
Dudum cited Canada's experience with weight-loss generics, where average monthly orders rose more than 50% after their introduction. Management sees broader access, greater retention and in-house fulfillment as longer-term margin opportunities.
HIMS Expands AI Care and New Treatment Categories
Chief technology officer Mohamed ElShenawy said that the AI-native experience reached 70% of weight-loss subscribers at quarter-end. Customers with access sent four times as many messages, while routine response times fell to minutes.
Dudum also outlined injectable and oral testosterone treatments and a Peptides+ launch planned for November. Okupe said that initial peptide revenue would not materially affect fourth-quarter results.
During Needham's regulatory questioning, Dudum emphasized that additional peptides, including BPC-157 and TB-500, depend on final regulatory decisions. The company plans to phase investment accordingly.
Hims Maintains a Longer-Term Investment Focus
Dudum presented metabolic health as the gateway to a broader relationship covering multiple treatments and ongoing care. International brand consolidation and AI-supported clinical services remain central priorities.
Okupe expects another quarter of potential subscriber pressure as U.S. marketing stays measured. Despite near-term margin and investment demands, management continues to target positive free cash flow for 2026 and 2027.
Growth, Momentum and combined VGM Score are all C, reflecting middle-range assessments rather than the stronger A or B grades favored alongside top-ranked stocks. The Zacks Rank may change as analysts revise earnings estimates following the third-quarter results.
View the Zacks #1 Rank List
Image: Bigstock
HIMS Q3 Earnings Call Highlights Marketing Reset and Margin Pressure
Key Takeaways
Hims & Hers Health, Inc. (HIMS - Free Report) is prioritizing a broader weight-loss offering and international expansion over immediate subscriber gains following its third-quarter 2026 earnings call. Management expects the changes to position the platform for renewed customer acquisition in early 2027.
Revenues rose 49% year over year to $890.4 million, missing the Zacks Consensus Estimate of $893.4 million. The company reported earnings of $0.03 per share, which missed the consensus mark of $0.07. The discussion centered on investment timing, weakening gross margins and the economics of branded treatments.
Hims & Hers Health, Inc. Price, Consensus and EPS Surprise
Hims & Hers Health, Inc. price-consensus-eps-surprise-chart | Hims & Hers Health, Inc. Quote
HIMS Holds Back Marketing Ahead of Weight-Loss Expansion
Chief executive officer Andrew Dudum said that the company deliberately moderated U.S. weight-loss marketing while preparing new medications, pricing options and longer subscription plans. The decision reduced near-term customer acquisition.
Subscribers reached 2.8 million, up 13% year over year but down 100,000 sequentially. Chief financial officer Yemi Okupe linked the decline to restrained domestic spending and international brand transitions.
Asked by Canaccord Genuity about subscriber trends, Okupe said that marketing would intensify around the first-quarter seasonal demand peak. He expects subscriber growth to recover after the expanded offering becomes available.
HIMS Broadens Drug Access Through Two Partners
Dudum highlighted plans to add Eli Lilly's Zepbound and Foundayo alongside Novo Nordisk's Wegovy products, with CagriSema planned once available. Multi-month subscriptions will offer additional pricing flexibility.
A Needham analyst questioned whether the marketing pullback reflected weaker returns. Dudum emphasized product assortment and subscription improvements rather than identifying deteriorating demand as the reason.
Okupe added that the company has previously seen broader selection support acquisition and retention. He expects acquisition benefits beginning in the first quarter, with retention benefits developing through 2027.
HIMS Cuts Profit Outlook Despite International Growth
Okupe narrowed full-year revenue guidance to $3.13 billion-$3.15 billion but lowered adjusted EBITDA guidance to $257 million-$277 million, reflecting planned international pricing and marketing investments and revenue deferrals.
Fourth-quarter guidance calls for revenues of $875 million-$895 million and adjusted EBITDA of $70 million-$90 million. Management also expects at least $20 million of full-year revenue and adjusted EBITDA pressure from membership deferrals.
International revenues reached $233 million, including roughly $135 million from Eucalyptus. Okupe raised his 2026 international revenue expectation to at least $650 million from $600 million as Hims & Hers expands across the United Kingdom, Germany and Australia.
HIMS Faces Branded Drug Margin Trade-Offs
Gross margin fell to 57% from 74% a year earlier, reflecting the growing share of lower-margin branded weight-loss products and international operations.
During Morgan Stanley's questioning, Okupe said the full-quarter contribution from Eucalyptus made international mix particularly significant. He stressed adjusted EBITDA dollars and free cash flow rather than near-term gross margin recovery.
Dudum cited Canada's experience with weight-loss generics, where average monthly orders rose more than 50% after their introduction. Management sees broader access, greater retention and in-house fulfillment as longer-term margin opportunities.
HIMS Expands AI Care and New Treatment Categories
Chief technology officer Mohamed ElShenawy said that the AI-native experience reached 70% of weight-loss subscribers at quarter-end. Customers with access sent four times as many messages, while routine response times fell to minutes.
Dudum also outlined injectable and oral testosterone treatments and a Peptides+ launch planned for November. Okupe said that initial peptide revenue would not materially affect fourth-quarter results.
During Needham's regulatory questioning, Dudum emphasized that additional peptides, including BPC-157 and TB-500, depend on final regulatory decisions. The company plans to phase investment accordingly.
Hims Maintains a Longer-Term Investment Focus
Dudum presented metabolic health as the gateway to a broader relationship covering multiple treatments and ongoing care. International brand consolidation and AI-supported clinical services remain central priorities.
Okupe expects another quarter of potential subscriber pressure as U.S. marketing stays measured. Despite near-term margin and investment demands, management continues to target positive free cash flow for 2026 and 2027.
HIMS Zacks Rank and Style Scores Signal Caution
HIMS carries a Zacks Rank #3 (Hold), indicating a neutral near-term ranking. Its Value Score of D points to less attractive valuation characteristics under the Zacks methodology. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Growth, Momentum and combined VGM Score are all C, reflecting middle-range assessments rather than the stronger A or B grades favored alongside top-ranked stocks. The Zacks Rank may change as analysts revise earnings estimates following the third-quarter results.